Peripheral neuropathy and BTKis in Waldenström: a response?
作者信息
Briani Chiara, Ferrero Bruno, Salvalaggio Alessandro, Ragaini Simone, Amaducci Enrico, Dogliotti Irene, Visentin Andrea, Ferrero Simone
机构信息
Neurology Unit, Department of Neurosciences, University of Padua, Padua, Italy.
Department of Neurosciences, University of Turin, Turin, Italy.
出版信息
Blood Adv. 2025 Aug 26;9(16):4319-4320. doi: 10.1182/bloodadvances.2025016734.
Abstract
摘要
相似文献
1
Peripheral neuropathy and BTKis in Waldenström: a response?华氏巨球蛋白血症中的周围神经病变与布鲁顿酪氨酸激酶抑制剂：一种反应？
Blood Adv. 2025 Aug 26;9(16):4319-4320. doi: 10.1182/bloodadvances.2025016734.
2
Cardiovascular Adverse Events Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis.与第二代布鲁顿酪氨酸激酶抑制剂治疗相关的心血管不良事件：系统评价和荟萃分析。
Clin Ther. 2024 Feb;46(2):134-145. doi: 10.1016/j.clinthera.2023.11.014. Epub 2023 Dec 14.
3
When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenario.当华氏巨球蛋白血症累及肾脏时：病例系列描述及“罕见中的罕见”情况的处理
Cancer Rep (Hoboken). 2024 Apr;7(4):e2062. doi: 10.1002/cnr2.2062.
4
A Case Series of Unilateral Peripheral Neuropathy.单侧周围神经病变病例系列
J Peripher Nerv Syst. 2025 Jun;30(2):e70033. doi: 10.1111/jns.70033.
5
Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia.老年慢性淋巴细胞白血病患者一线使用维奈克拉或布鲁顿酪氨酸激酶抑制剂停药后的真实世界治疗模式
JCO Oncol Pract. 2025 Aug;21(8):1124-1133. doi: 10.1200/OP.24.00220. Epub 2024 Dec 20.
6
Bruton's tyrosine kinase inhibition for the treatment of allergic disorders.布鲁顿酪氨酸激酶抑制剂治疗过敏疾病。
Ann Allergy Asthma Immunol. 2024 Jul;133(1):33-42. doi: 10.1016/j.anai.2024.03.002. Epub 2024 Mar 14.
7
Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study.奥妥珠单抗用于华氏巨球蛋白血症患者的诱导和维持治疗：一项开放标签、单臂2期研究。
EClinicalMedicine. 2025 Jul 25;86:103383. doi: 10.1016/j.eclinm.2025.103383. eCollection 2025 Aug.
8
Burden and predictors of peripheral neuropathy among cultivators and laborers using biothesiometer at primary healthcare setting: A cross-sectional study from Nutakkhi, Guntur, Andhra Pradesh.在初级卫生保健机构使用生物感觉阈值测量仪的耕作者和劳动者中周围神经病变的负担及预测因素：来自安得拉邦贡图尔努塔克希的一项横断面研究
J Family Med Prim Care. 2025 Jul;14(7):2709-2715. doi: 10.4103/jfmpc.jfmpc_1871_24. Epub 2025 Jul 21.
9
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.度洛西汀用于治疗疼痛性神经病变、慢性疼痛或纤维肌痛。
Cochrane Database Syst Rev. 2014 Jan 3;2014(1):CD007115. doi: 10.1002/14651858.CD007115.pub3.
10
Association Between Serum Neuron-specific Enolase Levels and Diabetic Neuropathy in Patients With Diabetes Mellitus: A Cross-sectional Study.糖尿病患者血清神经元特异性烯醇化酶水平与糖尿病神经病变的关联：一项横断面研究
Cureus. 2025 Jul 3;17(7):e87214. doi: 10.7759/cureus.87214. eCollection 2025 Jul.
本文引用的文献
1
Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and management.伴有抗髓鞘相关糖蛋白抗体的神经病：诊断、病理生理学及管理的最新进展
J Neurol Neurosurg Psychiatry. 2025 Mar 24;96(4):340-349. doi: 10.1136/jnnp-2024-334678.
2
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.布鲁顿酪氨酸激酶抑制剂用于华氏巨球蛋白血症的3期ASPEN研究中的周围神经病变
Blood Adv. 2025 Feb 25;9(4):722-728. doi: 10.1182/bloodadvances.2024014115.
3
Repurposing chemotherapy-induced peripheral neuropathy grading.重新利用化疗引起的周围神经病分级。
Eur J Neurol. 2024 Dec;31(12):e16457. doi: 10.1111/ene.16457. Epub 2024 Sep 16.
4
Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.抗髓鞘相关糖蛋白神经病 75 例患者的突变谱：临床和血液治疗反应及新治疗靶点提示。
Neurol Neuroimmunol Neuroinflamm. 2023 May 3;10(4). doi: 10.1212/NXI.0000000000200122. Print 2023 Jul.
5
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up.利妥昔单抗治疗髓鞘相关糖蛋白脱髓鞘多发性神经病的疗效：2 年随访期间的临床、血液学和神经生理学相关性。
Eur J Neurol. 2022 Dec;29(12):3611-3622. doi: 10.1111/ene.15553. Epub 2022 Sep 25.
6
From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.从具有神经学意义的单克隆丙种球蛋白病的生物学机制到治疗方法
Cancers (Basel). 2022 Mar 18;14(6):1562. doi: 10.3390/cancers14061562.
7
The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic Neuropathy.副蛋白血症性神经病的广泛病理生理机制。
Neurology. 2021 Feb 2;96(5):214-225. doi: 10.1212/WNL.0000000000011324. Epub 2020 Dec 4.
8
Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy.商业 ELISA 检测抗 MAG 抗体在神经病变患者中的敏感性和特异性。
J Neuroimmunol. 2020 Aug 15;345:577288. doi: 10.1016/j.jneuroim.2020.577288. Epub 2020 Jun 8.
9
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.化疗诱导的周围神经病结局测量标准化研究：从共识到第一个有效性和可靠性研究结果。
Ann Oncol. 2013 Feb;24(2):454-462. doi: 10.1093/annonc/mds329. Epub 2012 Aug 21.
10
Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies.用于免疫介导的周围神经病的 Rasch 构建总体残疾量表（R-ODS）。
Neurology. 2011 Jan 25;76(4):337-45. doi: 10.1212/WNL.0b013e318208824b.
Zotero 插件